Despite the promise of initial pre-clinical work on another anti-CD40 mAb, dacetuzumab (SGN40), demonstrating ADCC that was further enhanced by combining it with lenolidomide [46], development beyond a phase I dose escalation study appears to have been halted in CLL after it demonstrated minimal clinical activity as a single agent [47]. This evidence concerns the gene CD40 and B-cell chronic lymphocytic leukemia.